SCHEMBL1979040

SCHEMBL1979040

CC(C)(C)OC(=O)N1CCC(c2ccc(O)cc2O)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
MAPT P10636 1/20 0.53
THRB P10828 1/20 0.53
ESR2 Q92731 1/20 0.51
GPR119 Q8TDV5 6/20 0.49
PTPN2 P17706 1/20 0.47
PTPN1 P18031 1/20 0.47
PTPN6 P29350 1/20 0.47
PDK1 Q15118 1/20 0.47
PDK2 Q15119 1/20 0.47
PDK3 Q15120 1/20 0.47
PDK4 Q16654 1/20 0.47
SCN9A Q15858 1/20 0.47
KMT2A Q03164 1/20 0.46
TGFBR1 P36897 1/20 0.46
HTT P42858 1/20 0.46
NAMPT P43490 1/20 0.46
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473362 0.92 PDE4B (0.50) KDM4EMAPTTHRBESR2GPR119
SCHEMBL17398401 0.90 KDM4E (0.53) KDM4EMAPTTHRBESR2GPR119
SCHEMBL12713081 0.88 GPR119 (0.57) KDM4EMAPTTHRBGPR119PTPN2
SCHEMBL19103521 0.88 KDM4E (0.52) KDM4EMAPTTHRBESR2GPR119
SCHEMBL30493274 0.88 KDM4E (0.52) KDM4EMAPTTHRBESR2GPR119
SCHEMBL31443726 0.87 NR1H2 (0.54) KDM4EMAPTTHRBGPR119PTPN2
SCHEMBL21937098 0.87 GPR119 (0.57) KDM4EMAPTTHRBESR2GPR119
SCHEMBL30493288 0.87 GPR119 (0.57) KDM4EMAPTTHRBESR2GPR119
SCHEMBL17398495 0.87 ESR2 (0.52) KDM4EMAPTTHRBESR2GPR119
SCHEMBL3547383 0.87 SMN1; SMN2 (0.53) KDM4EMAPTTHRBGPR119KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9650337-B2 Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-05-16 US disclosed
US-9650337-B2 Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-05-16 US disclosed
EP-2956438-B1 METHOD FOR SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE GALDERMA RES & DEV (FR) 2017-03-22 EP disclosed
US-20150376126-A1 METHOD FOR THE SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND NOVEL COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-12-31 US disclosed
US-20150376126-A1 METHOD FOR THE SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND NOVEL COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-12-31 US disclosed
WO-2014125233-A2 METHOD FOR SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND NOVEL COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-08-21 WO disclosed
EP-2509945-B1 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RES & DEV (FR) 2014-03-05 EP disclosed
US-20120323012-A1 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-12-20 US disclosed
EP-2509945-A1 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF Galderma Research & Development (FR) 2012-10-17 EP disclosed
WO-2011070080-A1 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120323012-A1 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF TYR, DDT, TH KDM4E 787/4885MAPT 2154/4885THRB 2534/4885
US-20150376126-A1 METHOD FOR THE SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND NOVEL COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE HPD, CYP4B1, PAH KDM4E 224/4885MAPT 2211/4885THRB 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.